Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AGTCNASDAQ:ALECNASDAQ:CCCCNASDAQ:ENTX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAGTCApplied Genetic Technologies$0.39$0.39$0.23▼$2.83$26.62M1.55943,490 shsN/AALECAlector$1.18+13.0%$1.19$0.87▼$6.78$117.49M0.76814,664 shs1.41 million shsCCCCC4 Therapeutics$1.47-4.5%$1.67$1.09▼$7.66$104.38M3.11.40 million shs1.17 million shsENTXEntera Bio$2.15-3.2%$1.92$1.41▼$2.79$97.66M1.5175,960 shs8,407 shsThese 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAGTCApplied Genetic Technologies0.00%0.00%0.00%0.00%0.00%ALECAlector+1.95%-14.34%+10.90%-40.29%-79.87%CCCCC4 Therapeutics+3.34%-5.21%+28.22%-56.48%-76.05%ENTXEntera Bio+1.61%-0.67%+36.73%-8.85%-9.59%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAGTCApplied Genetic TechnologiesN/AN/AN/AN/AN/AN/AN/AN/AALECAlector3.5831 of 5 stars3.11.00.04.52.71.70.6CCCCC4 Therapeutics2.2438 of 5 stars3.32.00.00.02.42.50.6ENTXEntera Bio1.5652 of 5 stars3.54.00.00.00.00.80.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAGTCApplied Genetic Technologies 0.00N/AN/AN/AALECAlector 2.14Hold$4.00240.43% UpsideCCCCC4 Therapeutics 2.50Moderate Buy$12.00716.33% UpsideENTXEntera Bio 3.00Buy$10.00365.12% UpsideCurrent Analyst Ratings BreakdownLatest AGTC, ALEC, CCCC, and ENTX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/9/2025ALECAlectorHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$7.00 ➝ $10.003/18/2025ENTXEntera BioHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.00 ➝ $10.003/7/2025ALECAlectorMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingUnderweight$3.00 ➝ $1.502/27/2025ALECAlectorHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$7.00 ➝ $7.002/14/2025CCCCC4 TherapeuticsUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold(Data available from 5/9/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAGTCApplied Genetic Technologies$320K83.19N/AN/A$0.26 per share1.51ALECAlector$100.56M1.17N/AN/A$1.41 per share0.83CCCCC4 Therapeutics$35.58M2.93N/AN/A$4.07 per share0.36ENTXEntera Bio$181K539.53N/AN/A$0.36 per share5.97Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAGTCApplied Genetic Technologies-$68.94M-$1.46N/AN/AN/AN/A-192.90%-92.54%N/AALECAlector-$130.39M-$1.23N/AN/AN/A-257.54%-108.77%-27.03%5/14/2025 (Estimated)CCCCC4 Therapeutics-$132.49M-$1.51N/AN/AN/A-313.35%-42.45%-27.55%5/14/2025 (Estimated)ENTXEntera Bio-$8.89M-$0.25N/AN/AN/AN/A-107.24%-92.29%5/9/2025 (Estimated)Latest AGTC, ALEC, CCCC, and ENTX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025Q1 2025ALECAlector-$0.46N/AN/AN/A$4.25 millionN/A5/9/2025Q1 2025ENTXEntera Bio-$0.07-$0.06+$0.01-$0.06N/AN/A5/7/2025Q1 2025CCCCC4 Therapeutics-$0.48-$0.37+$0.11-$0.37$3.54 million$7.20 million3/28/2025Q4 2024ENTXEntera Bio-$0.08-$0.06+$0.02-$0.06$0.04 million$0.04 million2/27/2025Q4 2024CCCCC4 Therapeutics-$0.44-$0.49-$0.05-$0.49$4.43 million$5.18 million2/26/2025Q4 2024ALECAlector-$0.61-$0.02+$0.59-$0.02$20.41 million$54.24 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAGTCApplied Genetic TechnologiesN/AN/AN/AN/AN/AALECAlectorN/AN/AN/AN/AN/ACCCCC4 TherapeuticsN/AN/AN/AN/AN/AENTXEntera BioN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAGTCApplied Genetic Technologies0.391.401.40ALECAlectorN/A3.293.29CCCCC4 TherapeuticsN/A6.316.31ENTXEntera BioN/A6.616.61Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAGTCApplied Genetic Technologies22.05%ALECAlector85.83%CCCCC4 Therapeutics78.81%ENTXEntera Bio14.11%Insider OwnershipCompanyInsider OwnershipAGTCApplied Genetic Technologies4.10%ALECAlector9.10%CCCCC4 Therapeutics8.55%ENTXEntera Bio10.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAGTCApplied Genetic Technologies8367.63 million64.86 millionOptionableALECAlector27099.99 million89.02 millionOptionableCCCCC4 Therapeutics15071.01 million64.55 millionOptionableENTXEntera Bio2045.42 million31.88 millionOptionableAGTC, ALEC, CCCC, and ENTX HeadlinesRecent News About These CompaniesEntera Bio Announces First Quarter 2025 Financial Results and Business UpdatesMay 9 at 4:15 PM | globenewswire.comEntera Bio (ENTX) Expected to Announce Earnings on FridayMay 8 at 1:23 AM | americanbankingnews.comEntera Bio (ENTX) to Release Earnings on FridayMay 4, 2025 | marketbeat.comEntera Bio (NASDAQ:ENTX) Trading Up 5.6% - Time to Buy?April 26, 2025 | marketbeat.comEntera Bio announces highlights from presentation at WCO-IFO-ESCEO on EB613April 15, 2025 | markets.businessinsider.comEntera Bio Reports Transformative Year in 2024March 29, 2025 | tipranks.comEntera Bio Announces Full Year 2024 Financial Results and Provides Business UpdatesMarch 28, 2025 | globenewswire.comEntera Bio Ltd.March 26, 2025 | wsj.comOPKO Health, Entera Bio Partner on Oral Dual Agonist GLP-1March 19, 2025 | contractpharma.comOpko Health, Entera Bio to Collaborate on Tablet for Obesity, Metabolic and Fibrotic DisordersMarch 17, 2025 | marketwatch.comOpko, Entera share ownership of first oral GLP-1/glucagon agonist set to enter clinicMarch 17, 2025 | fiercebiotech.comOpko Health, Entera Bio enter collaboration agreement for GLP-1/glucagon peptideMarch 17, 2025 | markets.businessinsider.comOpko Health, Entera Bio enter into collaboration agreementMarch 17, 2025 | markets.businessinsider.comEntera Bio Collaborates with OPKO for Oral GLP-1/GlucagonMarch 17, 2025 | tipranks.comOPKO Health and Entera Bio Enter into Collaboration Agreement to Advance Oral GLP-1/Glucagon Tablet Candidate into the Clinic to Treat Obesity and Metabolic DisordersMarch 17, 2025 | globenewswire.comEntera Bio to Participate in Upcoming EventsFebruary 24, 2025 | globenewswire.comEntera Bio announces acceptance of EB613 abstracts for WCO-IOF-ESCEOFebruary 19, 2025 | markets.businessinsider.comIs Entera Bio (NASDAQ:ENTX) In A Good Position To Deliver On Growth Plans?February 6, 2025 | uk.finance.yahoo.comEntera Bio Ltd. to Present at Oppenheimer 35th Annual Healthcare Life Sciences ConferenceJanuary 27, 2025 | quiverquant.comEntera Bio to Present at the Oppenheimer 35th Annual Healthcare Life Sciences ConferenceJanuary 27, 2025 | globenewswire.comEntera Bio Buy Rating: Strong Financials, Strategic Developments, and Promising Pipeline Drive Analyst ConfidenceNovember 12, 2024 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeAGTC, ALEC, CCCC, and ENTX Company DescriptionsApplied Genetic Technologies NASDAQ:AGTCApplied Genetic Technologies Corporation, a clinical-stage biotechnology company, develops transformational genetic therapies for patients suffering from rare and debilitating diseases. Its advanced product candidates include three ophthalmology development programs across two targets, including X-linked retinitis pigmentosa, which is in the Phase 1/2 clinical trials; and achromatopsia that is in Phase 1/2 clinical trials. It is also developing an optogenetic product candidate to treat advanced retinal disease. In addition, the company has initiated one preclinical program in otology; preclinical program in dry age-related macular degeneration; and two preclinical programs in targeting central nervous system disorders, including frontotemporal dementia and amyotrophic lateral sclerosis. It has collaboration agreements with University of Florida; Bionic Sight, Inc.; and Otonomy, Inc. The company was incorporated in 1999 and is headquartered in Alachua, Florida.Alector NASDAQ:ALEC$1.18 +0.14 (+12.98%) As of 03:58 PM EasternAlector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, an immune activity in the brain with genetic links to multiple neurodegenerative disorders, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. The company also offers AL002, a product candidate that is in Phase II clinical trial for the treatment of Alzheimer's disease. Alector, Inc. has a collaboration agreement with Adimab, LLC for the research and development of antibodies; and a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of monoclonal antibodies, such as AL001 and AL101 to treat neurodegenerative diseases. The company was founded in 2013 and is headquartered in South San Francisco, California.C4 Therapeutics NASDAQ:CCCC$1.47 -0.07 (-4.55%) As of 04:00 PM EasternC4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma, currently under Phase 1/2 clinical trials. The company is also developing CFT1946, an orally bioavailable BiDAC degrader targeting V600X mutant BRAF to treat melanoma, non-small cell lung cancer (NSCLC), colorectal cancer, and other solid malignancies, currently under Phase 1/2 clinical trials; and CFT8919, an orally bioavailable, allosteric, and mutant-selective BiDAC degrader of epidermal growth factor receptor, or EGFR, with an L858R mutation in NSCLC. It has strategic collaborations with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; Biogen MA, Inc.; Betta Pharmaceuticals, Co., Ltd.; and Merck Sharp & Dohme, LLC, as well as Calico Life Sciences LLC. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.Entera Bio NASDAQ:ENTX$2.15 -0.07 (-3.15%) As of 03:59 PM EasternEntera Bio Ltd., a clinical-stage company, focuses on the development and commercialization of orally delivered peptide and protein therapeutics for unmet medical needs. The company's product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of stress fractures. Its other product candidate is GLP-2, which is in preclinical trial for the treatment of short bowl syndrome; and OXM for the treatment of obesity and metabolic diseases. The company has a research collaboration and license agreement with the Amgen Inc. for the development and discovery of clinical candidates in the field of inflammatory disease and other serious illnesses. Entera Bio Ltd. was incorporated in 2009 and is based in Jerusalem, Israel. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Taiwan Semiconductor Has a New Reason to Rally on Chip Curbs Why Nearly 20 Analysts Raised Meta Price Targets Post-Earnings Strategists Say Hold: Stocks May Beat the 'Sell in May' Trend What the ExtraHop Deal Means for CrowdStrike DoorDash’s Uptrend Is Gaining Momentum in 2025 Why Flutter Entertainment May Be a Resilient Sports Betting Stock OXY Stock Rebound Begins Following Solid Earnings Beat Is Energy Transfer Undervalued or a Value Trap? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
